Capital International Inc. CA Sells 3,284 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Inc. CA reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,292 shares of the company’s stock after selling 3,284 shares during the period. Capital International Inc. CA owned 0.12% of CRISPR Therapeutics worth $3,908,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CRSP. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the 4th quarter worth about $39,000. Western Pacific Wealth Management LP raised its stake in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the third quarter valued at about $40,000. Spire Wealth Management lifted its stake in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth approximately $80,000. 69.20% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares in the company, valued at approximately $7,673,353.80. This trade represents a 5.23 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CRSP shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, April 9th. Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Friday, March 21st. The Goldman Sachs Group reduced their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Finally, Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $37.77 on Monday. The stock’s fifty day moving average price is $40.93 and its 200 day moving average price is $43.73. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market cap of $3.24 billion, a price-to-earnings ratio of -8.64 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.